The FDA approved Abbott’s FreeStyle Libre continuous glucose monitoring (CGM) system for 14-day use last Friday.
The approval makes Abbott’s continuous glucose monitor the longest lasting self-applied personal glucose sensor available on the market, according to a company press release.
“With the new FreeStyle Libre 14 day system, people with diabetes will now have extended access to their glucose data with a high degree of accuracy, which will improve their experience and help empower them to better manage their condition,” remarked Jared Watkin, senior vice president, of Abbott Diabetes Care.
The FreeStyle Libre system (for 10-day use) was previously approved by the FDA in September 2017.
The device was the first on the market to eliminate the need for routine, painful and much-avoided finger prick tests to check blood glucose levels. It works by having a small sensor wire inserted below the skin’s surface that continuously monitors glucose levels.
Patients use a “scanner” above the sensor to check blood glucose levels. It’s helpful for patients to avoid hyperglycemia (when glucose levels are too high) and hypoglycemia (when glucose levels are too low).
A study published in the Lancet, funded by Abbott Diabetes Care, found that people using the CGM spent significantly less time in a hypoglycemia state than those who used traditional methods to monitor their blood glucose.
The FreeStyle Libre 14 day system will be available via prescription in the coming months at participating pharmacies and durable medical equipment suppliers in the U.S.
Image Credit: Shutterstock.
- “Abbott’s FreeStyle® Libre 14 Day Flash Glucose Monitoring System Now Approved in U.S.” (2018, Jul. 27). Retrieved from https://www.prnewswire.com/news-releases/abbotts-freestyle-libre-14-day-flash-glucose-monitoring-system-now-approved-in-us-300687894.html.